IGC Pharma (IGC) AI Stock Analysis

• Market Cap: $25.75M
• Dividend Yield: N/A
• Average Volume (3M): 229.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.33
• Revenue Growth: -5.50%
• EPS Growth: 56.57%
• Country: US
• Employees: 67
• Sector: Healthcare
• Sector Strength: 39
• Industry: Conglomerates
• EPS (TTM): -0.02
• Shares Outstanding: 83,891,590
• 10 Day Avg. Volume: 221,928
• 30 Day Avg. Volume: 229,767
• PEG Ratio: -0.20
• Price to Book (P/B): 2.13
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -21.09
• Enterprise Value/Market Cap: 1.78
• Enterprise Value/Revenue: 9.52
• Enterprise Value/Gross Profit: 72.22
• Enterprise Value/Ebitda: -1.32
• 1Y Price Target: $4.25
• Price Target Upside: 1316.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: $0.50 ▲(66.67%Upside)

IGC Pharma's overall stock score is significantly influenced by its financial challenges, including declining revenues and negative cash flow, which weigh heavily on its prospects. However, technical indicators and recent advancements in Alzheimer's research offer a counterbalance, providing some optimism. The valuation remains a concern due to the negative P/E ratio.

Positive Factors

Clinical Trials

IGC reported positive interim results from its Phase 2 trial for IGC-AD1, showing a significant reduction in agitation compared to placebo in patients with Alzheimer's disease.

Growth Opportunities

The company's strategic expansion into the $75 billion wellness industry with the launch of the Holiby brand offers new growth opportunities.

Market Potential

The large market potential for Alzheimer's treatments presents high rewards despite the risks, given the growing number of Americans affected by the disease.

Negative Factors

Market Risks

The large market potential for Alzheimer's disease treatment, due to the absence of a known cure and a growing number of patients, presents high rewards for the risks involved.

IGC Pharma Business Overview & Revenue Model

Company Description

India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. It operates through two segments, Infrastructure and Life Sciences. The company rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. It also develops cannabinoid-based products and therapies, such as hemp-based tinctures to treat anxiety, and enhance the lifestyle of patients suffering from Alzheimer's under the Hyalolex brand name; CBD based tinctures, capsules, and topical analgesic creams to treat pain under the Holief brand name; CBD powered beauty and skincare products under the Herbo brand name; and CBD infused beverages under the Sunday Seltzer brand. The company also engages in the wholesale of hemp extract under the Holi Hemp brand; production of products, such as lotions, creams, and oils, as well as white labeling support services; and extraction and distillation of crude oil into hemp extracts. It operates in the United States, India, Colombia, and Hong Kong. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

How the Company Makes Money

IGC Pharma generates revenue through the development and commercialization of pharmaceutical products and therapies, particularly those based on cannabinoid compounds. The company's revenue streams include sales of its proprietary products, licensing agreements, and potential collaborations with other pharmaceutical entities. Additionally, IGC may engage in partnerships with research institutions and healthcare organizations to further its research and development efforts, which could result in milestone payments and royalties. These partnerships and collaborations are significant contributors to the company's earnings, enabling it to expand its market presence and enhance its product offerings.

IGC Pharma Financial Statement Overview

Summary

IGC Pharma faces financial difficulties with declining revenues and significant losses. The balance sheet shows moderate leverage and a healthy equity ratio, but cash flow issues are critical, highlighting the need for strategic changes to improve operational efficiency and stabilize financial health.

Income Statement

IGC Pharma has faced significant challenges in maintaining revenue growth and profitability. The TTM (Trailing-Twelve-Months) shows a net loss with a declining revenue trend, as evidenced by a revenue decrease from $1,345,000 to $1,236,000. Margins are under pressure with a negative Net Profit Margin and EBIT Margin. While there is a gross profit, the high operating losses overshadow it, indicating inefficiencies or high expenditure relative to revenue.

Balance Sheet

The company's balance sheet shows moderate leverage with a debt-to-equity ratio that remains manageable. The equity ratio is relatively healthy, but there has been a noticeable decrease in stockholders' equity over recent periods. The declining total assets and cash position also suggest a weakening financial position, though the company maintains positive net debt, indicating more cash and equivalents than debt.

Cash Flow

IGC Pharma's cash flow statement indicates substantial cash outflows from operations, with negative free cash flow trends. The Operating Cash Flow to Net Income ratio is unfavorable, suggesting operational inefficiencies or high costs. Despite raising financing cash flows, the company struggles to generate positive cash from its core activities, which could hinder future operations without improvement.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	1.24M	1.34M	911.00K	397.00K	898.00K	4.07M
Gross Profit	636.00K	733.00K	442.00K	194.00K	113.00K	115.00K
EBITDA	-7.58M	-9.16M	-10.91M	-14.78M	-8.25M	-6.72M
Net Income	-8.81M	-13.00M	-11.51M	-15.02M	-8.81M	-8.10M
Balance Sheet
Total Assets	9.08M	9.90M	17.18M	26.83M	35.87M	28.98M
Cash, Cash Equivalents and Short-Term Investments	470.00K	1.20M	3.35M	10.46M	14.63M	12.34M
Total Debt	270.00K	345.00K	481.00K	488.00K	985.00K	535.00K
Total Liabilities	2.82M	2.58M	2.27M	2.94M	3.06M	2.45M
Stockholders Equity	6.26M	7.32M	14.91M	23.89M	32.80M	26.54M
Cash Flow
Free Cash Flow	-5.01M	-5.71M	-7.67M	-8.20M	-12.39M	-13.14M
Operating Cash Flow	-4.59M	-5.20M	-7.05M	-7.46M	-10.80M	-8.68M
Investing Cash Flow	-623.00K	-317.00K	-235.00K	-742.00K	3.39M	-9.55M
Financing Cash Flow	4.31M	3.52M	100.00K	4.14M	14.69M	-59.00K

IGC Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IGC, the sentiment is Negative. The current price of 0.3 is below the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.31, and below the 200-day MA of 0.33, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.82 is Neutral, neither overbought nor oversold. The STOCH value of 23.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IGC.

IGC Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RCMT	71 Outperform	$186.76M	14.55	42.38%	―	8.53%	-16.64%
SPLP	65 Neutral	$804.33M	3.75	24.14%	―	5.83%	72.33%
FIP	58 Neutral	$734.47M	―	-6.42%	1.88%	5.70%	36.39%
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
IGC	51 Neutral	$25.75M	―	-104.33%	―	-5.50%	56.57%
NNBR	51 Neutral	$115.02M	―	-17.87%	―	-7.16%	28.78%
TUSK	51 Neutral	$134.28M	―	-55.95%	―	-12.33%	-738.00%

IGC Pharma Corporate Events

IGC Pharma Highlights Alzheimer’s Research Progress

On June 17, 2025, IGC Pharma released an updated corporate presentation highlighting its clinical study advancements, which will be used in upcoming conferences and meetings with stakeholders. The presentation underscores the company’s progress in Alzheimer’s research, particularly with its IGC-AD1 drug candidate, which has undergone rigorous preclinical and regulatory reviews, showing promising results in reducing Alzheimer’s symptoms and meeting FDA standards.

The most recent analyst rating on (IGC) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on IGC Pharma stock, see the IGC Stock Forecast page.